Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
Overview
- Phase
- Phase 2
- Intervention
- Al18F-PSMA-BCH PET/CT
- Conditions
- Malignancy
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- Diagnostic value
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.
Detailed Description
Al18F-PSMA-BCH PET/CT will be performed on patients with suspected or clearly diagnosed PSMA positive-expressing tumors (including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.) , to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with suspected or clearly diagnosed PSMA positive-expressing tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.
- •Age is 18 or older; No gender limitation.
- •Signed the informed consent.
- •Willing and able to cooperate with all projects in this study.
Exclusion Criteria
- •Patients with serious neurological diseases,or gastrointestinal tract disease, cardiovascular disease, liver disease, kidney disease, blood system disease, endocrine system disease, respiratory system disease, immune deficiency disease, etc
- •Claustrophobia.
- •Pregnant or lactation women.
- •Received experimental drug or device within 1 month.
Arms & Interventions
Al18F-PSMA-BCH PET/CT
Al18F-PSMA-BCH PET/CT will be performed on patients with suspected or clearly diagnosed PSMA positive-expressing tumors.（including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.）
Intervention: Al18F-PSMA-BCH PET/CT
Outcomes
Primary Outcomes
Diagnostic value
Time Frame: through study completion, an average of 1 year
Sensitivity and Specificity of 18F-PSMA PET / CT for the diagnosis of Prostate Specific Membrane Antigen Positive Tumor